Tech Company Financing Transactions
Iroko Pharmaceuticals Funding Round
Iroko Pharmaceuticals closed a $75 million funding round on 11/21/2013. Investors included OrbiMed.
Transaction Overview
Company Name
Announced On
11/21/2013
Transaction Type
Debt
Amount
$75,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The financing will support general business operations and the launch of ZORVOLEX (diclofenac).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Rouse Blvd.
Philadelphia, PA 19112
USA
Philadelphia, PA 19112
USA
Phone
Website
Email Address
Overview
Iroko is dedicated to responsible pain management, with a pipeline of low-dose NSAIDs that are created using proprietary SoluMatrix Fine Particle Technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Vavricka
Chief Financial Officer
Fred Krieger
Chief Medical Officer
Clarence Young
VP - Bus. Development
Rohit Mehta
VP - General Counsel
Moji James
VP - Operations
Olalekan Bayode
VP - Operations
Humphrey Harte
VP - Product Management
Ariyapadi Krishnaraj
Browse more venture capital transactions:
Prev: 11/20/2013: Moderna venture capital transaction
Next: 11/21/2013: Sapheon venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs